CapeOX as neoadjuvant chemotherapy for locally advanced rectal cancer: might less be more?
CapeOX NAC presents notable benefits for LARC patients and its clinical significance may be underestimated. The NAR score demonstrates superior prognostic value over MRI-TRG.
Authors
- Yang Guo (ORCID: https://orcid.org/0000-0002-5628-4546)
- Kai Liu (ORCID: https://orcid.org/0000-0001-9413-6782)
- Huan Zhang
- Ye Xu (ORCID: https://orcid.org/0000-0003-0455-4556)
- Xiaoyan Zhou (ORCID: https://orcid.org/0000-0001-5103-783X)
- Dan Huang (ORCID: https://orcid.org/0000-0002-0956-780X)
- Tong Tong (ORCID: https://orcid.org/0000-0002-9180-8181)
- Tianan Guo (ORCID: https://orcid.org/0000-0002-1450-482X)
- Sanjun Cai
- Zhonglin Zhu
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-10-09
- DOI
- https://doi.org/10.1186/s12885-024-12972-6
- Citations
- 3
- Primary Topic
- Colorectal Cancer Surgical Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- National Natural Science Foundation of China